Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

Journal of the National Cancer Institute

Volumn 86, Issue 20, 1994, Pages 1534-1539

  Love, Richard R ^a   Wiebe, Donald A ^b   Feyzi, Jan M ^c   Newcomb, Polly A ^a   Chappell, Richard J ^c  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTOR;

BLOOD GLUCOSE; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOGEN; HUMANS; LIPIDS; POSTMENOPAUSE; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0028000253     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.20.1534     Document Type: Article

References (24)

1. Nayfield SG, Karp JE, Ford LG, et al: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459, 1991.
2. Cummings SR, Black DM, Rubin SM: Lifetime risks of hip, Colies’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2245-248, 1989
3. Grady D, Rubin SM, Petitti DB, et al: Hormone therapy to prevent disease and prolong life in postmenopausal women [see comment citations in Medline]. Ann Intern Med 117:1016-1037, 1992
4. Love RR, Wiebe DA, Newcomb PA, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860-864, 1991
5. Love RR, Surawicz TS, Williams EC: Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 152:317-320, 1992
6. Bruning PF, Bonfrer JM, Hart AA, et al: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58:497-499, 1988
7. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee [see comment citation in Medline]. BMJ 303:435-437, 1991
8. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of tamoxifen. The Stockholm Breast Cancer Study Group [see comment citation in Medline]. J Natl Cancer Inst 85:1398-1406, 1993
9. Scanu AM, Lawn RM, Berg K: Lipoprotein(a) and atherosclerosis. Ann Intern Med 115:209-218, 1991
10. Anderson KM, Wilson PW, Odell PM, et al: An updated coronary risk profile. A statement for health professionals. Circulation 83:356-362. 1991
11. Love RR, Newcomb PA, Wiebe DA, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer [see comment citation in Medline], J Natl Cancer Inst 82:1327-1332, 1990
12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
13. Levine DM, Sloan BJ, Donner JE, et al: Automated measurement of lipoprotein(a) by immunoturbidmetric analysis. Int J Clin Lab Res 22:173-178, 1992
14. 2+ precipitation. Clin Chem 28:1574-1578, 1982
15. Snedecor GW, Cochran WG: Statistical Methods, Seventh ed. Ames, Iowa: Iowa State Univ Press, 1980
16. Sherman DA, Stock JL, Heiniluoma KM, et al: Tamoxifen lowers Lp(a) in males with heart disease. Circulation 86(Suppl 1):338, 1992
17. Nabulsi AA, Folsom AR, White A, et al: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators [see comment citation in Medline]. N Engl J Med 328:1069-1075, 1993
18. Lobo RA: Estrogen and cardiovascular disease. Ann N Y Acad Sci 592:286-294; discussion 334-345, 1990
19. Yusuf S, Wines J, Friedman L: Overview of results of randomized clinical trials in heart disease II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 260:2259-2263, 1988
20. Ernst E, Resch KL: Fibnnogen as a cardiovascular risk factor: a meta-analysis and review of the literature [see comment citation in Medline]. Ann Intern Med 118:956-963, 1993
21. Meade TW, Mellows S, Brozovic M, et al: Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study [see comment citation in Medline], Lancet 2:533-537, 1986
22. Kannel WB, Wolf PA, Castelli WP, et al: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183-1186, 1987
23. Dahlen GH, Guyton JR, Attar M, et al: Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 74:758-765, 1986
24. MBewu AD, Durrington PN: Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 85:1-14, 1990